BioPharma Dive
BIO
News outlet

BioPharma Dive

biopharmadive.com · 1 feed
Stories, last 30 days
21
from 36 articles
Political lean
Not labelled yet
We have not rated this outlet yet
How fast it reports
About 9 hours after the first outlet
typical gap behind the first outlet on a story
First to report 1 of 21 stories (5%)

What it covers

Latest stories it covered

FDA declines approval of Summit Therapeutics’ ivonescimab for non-small cell lung cancer
Health

FDA declines approval of Summit Therapeutics’ ivonescimab for non-small cell lung cancer

The US Food and Drug Administration (FDA) declines to approve Summit Therapeutics’ investigational bispecific antibody ivonescimab for a non-small cell lung cancer (NSCLC) indicati...

1 day ago 6 sources 8
Eli Lilly to buy Calytrix Bio for up to $1.5 billion
Business

Eli Lilly to buy Calytrix Bio for up to $1.5 billion

Eli Lilly is set to acquire Calytrix Bio in a deal worth up to $1.5 billion. Calytrix is a privately held biotechnology company backed by JPMorgan Chase, and it is developing thera...

21 hours ago 4 sources 4
Johnson & Johnson agrees to buy Ollin Biosciences for about $2.2bn
Business

Johnson & Johnson agrees to buy Ollin Biosciences for about $2.2bn

Johnson & Johnson has agreed to acquire Ollin Biosciences, a clinical-stage biotech focused on therapies for serious eye diseases. Quartz and the Wall Street Journal Tech both repo...

1 day ago 6 sources 5
Blackstone to fund Pfizer’s monthly berobenatide Phase 3 obesity drug studies
Business

Blackstone to fund Pfizer’s monthly berobenatide Phase 3 obesity drug studies

Pfizer is securing as much as $1.5 billion from Blackstone to support development of its monthly obesity drug berobenatide, according to multiple outlets. The funding is tied to ad...

5 days ago 6 sources 6
PepGen reports promising early trial results for muscular dystrophy drug
Health

PepGen reports promising early trial results for muscular dystrophy drug

PepGen says early data from a small study of its muscular dystrophy treatment look promising. Across the limited trial findings, the company reports that its therapy is showing sig...

6 days ago 2 sources 3
FDA approves Bayer’s Sunharbo, a first-in-class Factor XIa stroke blood thinner
Business

FDA approves Bayer’s Sunharbo, a first-in-class Factor XIa stroke blood thinner

Bayer’s Sunharbo receives U.S. FDA approval as a once-daily blood thinner intended to reduce the risk of an additional stroke. Quartz reports the approval is based on trial results...

1 week ago 2 sources 0
Argenx agrees to acquire Unnatural Products for development of macrocyclic peptide medicines
Business

Argenx agrees to acquire Unnatural Products for development of macrocyclic peptide medicines

Argenx has agreed to acquire Unnatural Products, a biotechnology firm working on a macrocyclic peptide platform. One report says the deal would give Argenx control of the technolog...

1 week ago 2 sources 0
FDA investigates possible tumor risk in children treated with Novartis’ Zolgensma gene therapy
Health

FDA investigates possible tumor risk in children treated with Novartis’ Zolgensma gene therapy

The US Food and Drug Administration is investigating reports of tumors, including malignancies, in children who received Novartis’ one-time gene therapy Zolgensma for spinal muscul...

1 week ago 5 sources 32
Hims and Lilly agree on GLP-1 partnership amid Hims shift in drug practices
Business

Hims and Lilly agree on GLP-1 partnership amid Hims shift in drug practices

Hims and Hers reaches a deal with Lilly covering GLP-1 medicines, and Hims’ stock rises following the announcement. Under the agreement, Hims says it will stop future compounding o...

1 week ago 2 sources 1
CVS Health plans to split into two publicly traded companies separating pharmacies from insurance
Business

CVS Health plans to split into two publicly traded companies separating pharmacies from insurance

CVS Health announces plans to break up its business into two separate publicly traded companies, separating retail pharmacy operations from its insurance and prescription-benefit u...

1 week ago 20 sources 16
CMS finalizes 2027 outpatient payment rule cutting 340B drug payments and expanding site-neutral payments
Health

CMS finalizes 2027 outpatient payment rule cutting 340B drug payments and expanding site-neutral payments

Regulators finalize a CMS rule that changes Medicare payments starting in 2027, including major reductions for drugs covered under the 340B program and expanded “site-neutral” paym...

1 week ago 2 sources 96
Revolution Medicines’ Rasonque sees strong early sales as analysts reassess launch expectations
Business

Revolution Medicines’ Rasonque sees strong early sales as analysts reassess launch expectations

Revolution Medicines’ new pancreatic cancer drug, Rasonque, is getting a strong early commercial response, prompting Wall Street analysts to reassess projections. Across outlets, c...

1 week ago 3 sources 11
Novo Nordisk raises 2026 forecast as Wegovy pill sales top expectations
Business

Novo Nordisk raises 2026 forecast as Wegovy pill sales top expectations

Novo Nordisk raises its 2026 outlook again after third-quarter results show stronger-than-expected demand for its Wegovy weight-loss pill. Multiple outlets say the company increase...

1 week ago 10 sources 16
KFF projects 50% average rise in Medicare Part D premiums in 2027
Health

KFF projects 50% average rise in Medicare Part D premiums in 2027

Medicare Part D premiums are projected to increase sharply in 2027, with KFF analysis indicating an average rise of about 50%. News coverage highlights that the average monthly pre...

2 weeks ago 3 sources 10
DOL finalizes PBM disclosure rule requiring fee and compensation transparency for employers
Politics

DOL finalizes PBM disclosure rule requiring fee and compensation transparency for employers

The U.S. Department of Labor finalizes a rule aimed at increasing transparency in how pharmacy benefit managers (PBMs) are paid. Multiple outlets report the final requirements focu...

2 weeks ago 5 sources 205
HHS temporarily allows compounding pharmacies to make six unapproved peptides
Health

HHS temporarily allows compounding pharmacies to make six unapproved peptides

The U.S. Department of Health and Human Services (HHS) announces a policy that temporarily allows 503A compounding pharmacies to produce six specific peptides through patient-speci...

2 weeks ago 25 sources 34
Lilly’s retatrutide outperforms Ozempic in trial on weight loss and blood sugar control
Business

Lilly’s retatrutide outperforms Ozempic in trial on weight loss and blood sugar control

Eli Lilly reports that its experimental obesity and diabetes drug retatrutide, often described as a “triple-G” medicine, performs better than Novo Nordisk’s Ozempic in a head-to-he...

2 weeks ago 6 sources 12
Artiva to shut down autoimmune cell therapy program after patient deaths
Health

Artiva to shut down autoimmune cell therapy program after patient deaths

Artiva is winding down its autoimmune cell therapy work after two deaths reported in a trial of the approach, according to STAT+. The company says the recent fatalities are a setba...

2 weeks ago 2 sources 11
Judge rejects Novo Nordisk bid to halt Eli Lilly weight-loss drug ads
Business

Judge rejects Novo Nordisk bid to halt Eli Lilly weight-loss drug ads

A federal judge rejects Novo Nordisk’s request to block Eli Lilly from running advertising for its weight-loss drug(s), ruling that Novo did not show it would suffer meaningful, ir...

3 weeks ago 5 sources 11
Moderna and Merck cancer vaccine data leak sparks market selloff despite promising melanoma results
Business

Moderna and Merck cancer vaccine data leak sparks market selloff despite promising melanoma results

Moderna and Merck shares fall after partial clinical data for the personalised mRNA cancer vaccine with Merck leaks ahead of schedule, prompting investor concerns before the full r...

3 weeks ago 10 sources 13
Searching

Start typing to search stories...